Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 05/27 05:35:05 pm
4022.5 GBp   +0.27%
01:05p ASTRAZENECA : S faslodex met primary endpoint in first-line treatmen..
05/27 ASTRAZENECA : Faslodex demonstrates superiority to Arimidex in Phase..
05/27DJASTRAZENECA : Key EU Committee Backs AstraZeneca Diabetes Drug
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ASTRAZENECA PLC
01:05p ASTRAZENECA : S faslodex met primary endpoint in first-line treatment of advance..
05/27 ASTRAZENECA : Faslodex demonstrates superiority to Arimidex in Phase III study
05/27DJASTRAZENECA : Key EU Committee Backs AstraZeneca Diabetes Drug
05/27 ASTRAZENECA : Positive chmp opinion in eu for saxa/dapa
05/27 UPDATE : AstraZeneca Gets Positive Opinion On Saxa/Dapa
05/27 ASTRAZENECA : 's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in..
05/27 AstraZeneca potassium drug delayed by manufacturing snag
05/27DJASTRAZENECA : Says Faslodex Superior to Arimidex in Breast Cancer Treatment Tria..
05/27 TOP NEWS : AstraZeneca Gets Good Breast Cancer Treatment Results
05/27 ASTRAZENECA : S faslodex met primary endpoint in first-line treatment of advance..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials